Quantbot Technologies LP acquired a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 101,123 shares of the medical equipment provider's stock, valued at approximately $6,342,000.
A number of other large investors also recently modified their holdings of SNN. Clearstead Trust LLC bought a new stake in Smith & Nephew SNATS during the second quarter valued at about $25,000. Addison Advisors LLC purchased a new stake in shares of Smith & Nephew SNATS during the second quarter worth about $43,000. Allworth Financial LP purchased a new stake in shares of Smith & Nephew SNATS during the second quarter worth about $48,000. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS during the 4th quarter valued at approximately $27,000. Finally, Arax Advisory Partners raised its stake in Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 569 shares during the period. Hedge funds and other institutional investors own 25.64% of the company's stock.
Smith & Nephew SNATS Stock Performance
Shares of SNN opened at $29.29 on Friday. The company's fifty day moving average is $30.32 and its 200 day moving average is $31.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS, Inc. has a fifty-two week low of $28.56 and a fifty-two week high of $38.79.
Smith & Nephew SNATS Dividend Announcement
The firm also recently announced a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a $0.312 dividend. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the company. Zacks Research downgraded Smith & Nephew SNATS from a "hold" rating to a "strong sell" rating in a research note on Friday, August 7th. Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Morgan Stanley restated an "overweight" rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Thursday, June 4th. Finally, Barclays downgraded shares of Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $30.93.
View Our Latest Analysis on Smith & Nephew SNATS
Smith & Nephew SNATS Company Profile
(
Free Report)
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
